RxDoctor Payments Data

Moni Abraham, MD

Internal Medicine · Elmhurst, ILNPI 1275729436

Payments from drug & device makers

$2,028in general payments, 2019–2025

Across 93 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$421
  • Amgen$385
  • Lilly USA, LLC$258
  • Novartis$240
  • GSK$167
  • Gilead$125
  • plus $432 from 9 others

What the payments were for

  • Food & beverage$2,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,028 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$158,839
Medicare patients
433
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban34$51,486
JardianceEmpagliflozin41$51,118
EliquisApixaban45$37,848
Breo ElliptaFluticasone/Vilanterol46$24,489
JanuviaSitagliptin Phosphate20$22,359
RestasisCyclosporine15$10,155
TradjentaLinagliptin15$8,258
TyrvayaVarenicline Tartrate13$8,093
Atorvastatin Calcium719$6,620
VascepaIcosapent Ethyl15$5,576
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,274
Novolog FlexpenInsulin Aspart13$5,031
Amlodipine Besylate582$4,514
Losartan Potassium395$4,193
Levothyroxine Sodium412$4,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$117$59,37756 claims
Johnson & JohnsonXarelto$421$51,48634 claims
PfizerEliquis$72$37,84845 claims
GSKBreo Ellipta$167$24,48946 claims
Novo NordiskLevemir$56$1,45714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →